BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36097695)

  • 1. Enhancement of dendritic cell immunotherapy by recalling antigens for hepatocellular carcinoma in mice.
    Lee WC; Cheng CH; Lee CF; Hsu HY; Hsu PY; Wu TJ; Chan KM
    Immunotherapy; 2022 Oct; 14(15):1225-1236. PubMed ID: 36097695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of dendritic-based vaccine efficacy against hepatitis B virus-related hepatocellular carcinoma by two tumor-associated antigen gene-infected dendritic cells.
    Yang JY; Cao DY; Xue Y; Yu ZC; Liu WC
    Hum Immunol; 2010 Mar; 71(3):255-62. PubMed ID: 20036295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen-specific T cell response from dendritic cell vaccination using side population cell-associated antigens targets hepatocellular carcinoma.
    Li X; Zhang Z; Lin G; Gao Y; Yan Z; Yin H; Sun B; Wang F; Zhang H; Chen H; Cao D
    Tumour Biol; 2016 Aug; 37(8):11267-78. PubMed ID: 26951511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
    Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
    Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoimmune hepatic inflammation by vaccination of mice with dendritic cells loaded with well-differentiated hepatocellular carcinoma cells and administration of interleukin-12.
    Tamaki S; Homma S; Enomoto Y; Komita H; Zeniya M; Ohno T; Toda G
    Clin Immunol; 2005 Dec; 117(3):280-93. PubMed ID: 16246626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving immunotherapy of hepatocellular carcinoma (HCC) using dendritic cells (DC) engineered to express IL-12 in vivo.
    Vogt A; Sievers E; Lukacs-Kornek V; Decker G; Raskopf E; Meumann N; Büning H; Sauerbruch T; Strassburg CP; Schmidt-Wolf IG; Gonzalez-Carmona MA
    Liver Int; 2014 Mar; 34(3):447-61. PubMed ID: 23998316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy of Tumor RNA-Loaded Lipid Nanoparticles Against Hepatocellular Carcinoma.
    Zhang Y; Xie F; Yin Y; Zhang Q; Jin H; Wu Y; Pang L; Li J; Gao J
    Int J Nanomedicine; 2021; 16():1553-1564. PubMed ID: 33658783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
    Homma S; Komita H; Sagawa Y; Ohno T; Toda G
    Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous Tumor Cell Lysate-Loaded Dendritic Cell Vaccine Inhibited Tumor Progression in an Orthotopic Murine Model for Hepatocellular Carcinoma.
    Wang Q; Luan W; Warren L; Kadri H; Kim KW; Goz V; Blank S; Isabel Fiel M; Hiotis SP
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):574-582. PubMed ID: 26786094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory T Cell Inhibition by P60 Combined with Adenoviral AFP Transduced Dendritic Cells for Immunotherapy of Hepatocellular Carcinoma.
    Sadeghlar F; Seelemann J; Vogt A; Möhring C; Zhou T; Mahn R; Kornek M; Lukacs-Kornek V; Casares N; Lasarte JJ; Sarobe P; van Beekum C; Matthaei H; Manekeller S; Kalff J; Schmidt-Wolf IGH; Strassburg CP; Gonzalez-Carmona MA
    Immunol Invest; 2023 Nov; 52(8):966-984. PubMed ID: 37846958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models.
    Lu Z; Zuo B; Jing R; Gao X; Rao Q; Liu Z; Qi H; Guo H; Yin H
    J Hepatol; 2017 Oct; 67(4):739-748. PubMed ID: 28549917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell as therapeutic vaccines against tumors and its role in therapy for hepatocellular carcinoma.
    Sun K; Wang L; Zhang Y
    Cell Mol Immunol; 2006 Jun; 3(3):197-203. PubMed ID: 16893500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.
    Laureano RS; Sprooten J; Vanmeerbeerk I; Borras DM; Govaerts J; Naulaerts S; Berneman ZN; Beuselinck B; Bol KF; Borst J; Coosemans A; Datsi A; Fučíková J; Kinget L; Neyns B; Schreibelt G; Smits E; Sorg RV; Spisek R; Thielemans K; Tuyaerts S; De Vleeschouwer S; de Vries IJM; Xiao Y; Garg AD
    Oncoimmunology; 2022; 11(1):2096363. PubMed ID: 35800158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma.
    Cao DY; Yang JY; Yue SQ; Tao KS; Song ZS; Wang DS; Yang YL; Dou KF
    Cell Immunol; 2009; 259(1):13-20. PubMed ID: 19545862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
    Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
    J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.
    Waeckerle-Men Y; Uetz-von Allmen E; Fopp M; von Moos R; Böhme C; Schmid HP; Ackermann D; Cerny T; Ludewig B; Groettrup M; Gillessen S
    Cancer Immunol Immunother; 2006 Dec; 55(12):1524-33. PubMed ID: 16612599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal.
    Lee H; Park HJ; Sohn HJ; Kim JM; Kim SJ
    J Surg Res; 2011 Jul; 169(1):e43-50. PubMed ID: 21571303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.
    Palmer DH; Midgley RS; Mirza N; Torr EE; Ahmed F; Steele JC; Steven NM; Kerr DJ; Young LS; Adams DH
    Hepatology; 2009 Jan; 49(1):124-32. PubMed ID: 18980227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.